1 Min Read
Sept 28 (Reuters) - Biovie Inc
* BioVie announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.